Welcome to our dedicated page for Ptc Therapeutics SEC filings (Ticker: PTCT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
PTC Therapeutics filings document a Delaware biopharmaceutical company with common stock listed on the Nasdaq Global Select Market under PTCT. Its Form 8-K reports cover quarterly and annual financial results, Regulation FD disclosures, product and pipeline updates, FDA-related communications, and board or compensation matters.
Proxy materials describe annual meeting governance, director elections, executive compensation, equity awards and related shareholder matters. The filing record also includes disclosures tied to rare-disease programs such as Sephience™ (sepiapterin), votoplam and Translarna™ (ataluren), along with the company’s capital structure and public-company reporting obligations.
PTC Therapeutics files its annual report describing a rare-disease portfolio in transition. The company highlights growing contributions from Sephience for phenylketonuria, which gained approvals in the EU, United States, Japan and Brazil in 2025–2026, alongside established products Emflaza, Translarna, Evrysdi royalties and AADC gene therapy Upstaza/Kebilidi.
Translarna faces a major setback after the European Commission declined to renew its conditional approval for nonsense mutation Duchenne muscular dystrophy, creating a substantial risk to related revenue, while U.S. development has been halted. Emflaza’s U.S. market now contends with generic competition following orphan exclusivity expiry for older patients.
The company deepened its neurology pipeline, including Huntington’s disease candidate votoplam, licensed to Novartis with a $1.0 billion upfront payment and potential milestones plus a U.S. profit share, and continues work on vatiquinone for Friedreich ataxia after an FDA complete response letter. PTC also monetized all remaining Evrysdi royalties, receiving total consideration of $2.1 billion, and reports 82,774,730 shares of common stock outstanding as of February 18, 2026.
PTC Therapeutics reported strong fourth quarter and full-year 2025 results and provided 2026 guidance. Full-year 2025 product and royalty revenue was $831M, exceeding guidance, helped by Sephience, which generated $92M in fourth-quarter revenue and $111M for 2025 after its 2H 2025 launch.
For 2025, total revenues were $1,730,655,000, more than doubling from $806,780,000 in 2024, based on figures presented in thousands. Net income attributable to common stockholders was $682.6M, reversing a $363.3M loss in 2024, driven largely by $998.4M of collaboration and license revenue and despite a $98.6M negative adjustment to Translarna France sales allowances.
At December 31, 2025, cash, cash equivalents and marketable securities were $1.95B, total debt was $286.6M, and total liability for sale of future royalties was $2.31B, with stockholders’ deficit at $205.3M. For full-year 2026, projected GAAP R&D and SG&A expense is $775–$815M, and projected non-GAAP R&D and SG&A is $680–$720M after excluding $95M of expected stock-based compensation.
PTCT filed a Form 144 reporting the proposed sale of 3,019 shares of common stock that vested on 02/15/2026. The filing lists the shares as arising from Restricted Stock Vesting and identifies Fidelity Brokerage Services LLC in the securities section. The excerpt also lists multiple recent sales by Mark Boulding between 01/05/2026 and 02/18/2026, including transactions of 2,266, 1,739, and 4,879 shares on specific dates with corresponding proceeds shown.
PTCT reported proposed sales of common stock by an affiliated insider under Form 144.
The filing lists multiple sales by Eric Pauwels, including 40,290 shares on 12/17/2025 and 3,202 shares on 12/18/2025. The excerpt also shows 3,019 restricted shares vesting on 02/17/2026 as compensation.
PTCT submitted a Form 144 notice for the proposed sale of 65 common shares associated with restricted stock vesting on 02/17/2026. The filing also lists multiple insider sales during the prior three months by Neil G. Almstead and Zheng Y. Almstead, with individual transactions dated 11/24/2025 through 01/08/2026 and share amounts and gross proceeds disclosed for each trade.
PTCT submitted a Form 144 reporting a proposed sale of 3,056 common shares tied to restricted stock vesting on 02/17/2026. The filing also lists recent open-market sales by insiders, including Neil G. Almstead (examples shown: 35,572 shares on 11/24/2025 and 71,928 shares on 11/25/2025). The transactions are presented as issuer compensation and past sales over the prior three months.
PTCT — Pierre S. Szyika-Gravier filed a Form 144 to sell 2,992 common shares. The filing lists the sale date as 02/17/2026 and describes the securities as restricted stock vesting related to compensation. The notice also reports a prior sale of 2,139 shares on 01/06/2026.
PTCT filed a Form 144 reporting a proposed sale of 2,494 common shares arising from restricted stock vesting on 02/17/2026. The filing also lists recent dispositions by Christine Utter: 1,381 shares on 01/06/2026, 1,235 shares on 01/07/2026, and 1,034 shares on 01/08/2026, with reported proceeds for each trade.
Mark Boulding reported sales of company common stock. The filing lists 3,081 shares tied to restricted stock vesting dated 02/17/2026 and executed through Fidelity Brokerage Services LLC. The filing also itemizes prior dispositions in January 2026: 2,266 (01/05/2026), 1,739 (01/06/2026), 4,879 (01/07/2026), 4,033 (01/08/2026), and 2,314 (01/09/2026).
PTCT submitted a Form 144 reporting a proposed sale of 2,484 common shares tied to restricted stock vesting on 02/17/2026. The filing also lists three prior open-market sales by Lee S. Golden: 1,340 shares on 01/06/2026, 642 shares on 01/07/2026, and 866 shares on 01/08/2026